Feedback
Settings

Settings

Goto Application

6,096 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(USVMJSALORZVDV-SDBHATRESA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 610
1.WO/2025/235952HUMANIZED ANTI-CD84 ANTIBODIES
WO - 13.11.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No PCT/US2025/028746 Applicant CITY OF HOPE Inventor WILLIAMS, John C.
Provided herein are, inter alia, humanized antibodies which bind Cluster of Differentiation 84 (CD84) with high efficiency and specificity. The humanized antibodies provided herein include novel light and heavy chain domain CDRs and framework regions and are, inter alia, useful for treating cancer and other CD84-related diseases.
2.WO/2025/235527CRYSTALLINE FORMS OF A PPAR ALPHA ANTAGONIST
WO - 13.11.2025
Int.Class C07D 249/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
249Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
02not condensed with other rings
081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
10with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
12Oxygen or sulfur atoms
 Appl.No PCT/US2025/028011 Applicant TEMPEST THERAPEUTICS, INC. Inventor JOHNSON, Henry William Beecroft
Described herein are crystalline forms of a compound that is a PPARα antagonist, methods of making such crystalline forms, pharmaceutical compositions and medicaments comprising such crystalline forms, and methods of using such crystalline forms in the treatment of conditions, diseases, or disorders that would benefit from modulation of PPARα activity.
3.WO/2025/2350343-FLUORO-5-(((LS,2AR)-1,3,3,4, 4-PENTAFLUORO-2A-HYDROXY-2,2A, 3,4-TETRAHYDRO-LH-CYCLOPENTA[CD]INDEN-7- YL)OXY)- BENZONITRILE DOSING REGIMEN FOR USE IN THE TREATMENT OF CANCER
WO - 13.11.2025
Int.Class A61K 31/277
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
275Nitriles; Isonitriles
277having a ring, e.g. verapamil
 Appl.No PCT/US2024/056721 Applicant NIKANG THERAPEUTICS, INC. Inventor WANG, Keshi
Disclosed herein are methods of treating cancer with a hypoxia inducible factor-2α (HIF-2α) inhibitor, 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile ((Compound (I)) having the structure:
4.WO/2025/2352903-FLUORO-5-(((LS,2AR)-L, 3,3,4, 4-PENTAFLUORO-2A-HYDROXY-2,2A, 3,4-TETRAHYDRO-LH-CYCLOPENTA[CD]INDEN-7-YL)OXY)- BENZONITRILE DOSING REGIMEN FOR USE IN THE TREATMENT OF CANCER
WO - 13.11.2025
Int.Class A61K 31/277
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
275Nitriles; Isonitriles
277having a ring, e.g. verapamil
 Appl.No PCT/US2025/027249 Applicant NIKANG THERAPEUTICS, INC. Inventor WANG, Keshi
Disclosed herein are methods of treating cancer with a hypoxia inducible factor-2α (HIF-2α) inhibitor, 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile ((Compound (I)) having the structure: (I)
5.WO/2025/233437POLYPEPTIDE COMPRISING A CAPSID PROTEIN SEQUENCE
WO - 13.11.2025
Int.Class C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
 Appl.No PCT/EP2025/062576 Applicant A-SPECTAR GMBH Inventor SCHÖNFELD, Wolfgang
The present invention discloses a polypeptide comprising a capsid protein sequence consisting of eight core regions and seven loop modification regions, wherein the eight core regions are defined, respectively, by amino acid positions M1 to S309, P319 to R328, T340 to T342, M349 to F352, W359 to F362, V368 to Q373, T383 to T387 and T392 to N644 in the amino acid sequence according to SEQ ID NO: 1, wherein the eight core regions of the capsid protein sequence have at least 70 % sequence identity to the eight core regions of the amino acid sequence according to SEQ ID NO: 1 or SEQ ID NO: 2 at least in the range from R32 to N570, wherein the seven loop modification regions are defined, respectively, by amino acid positions A310 to I318, H329 to I339, I343 to T348, D353 to E358, A363 to D367, T374 to A382, and A388 to V391 in the amino acid sequence according to SEQ ID NO: 1, wherein at least one loop modification region of the capsid protein sequence differs from the corresponding loop modification region of the amino acid sequences according to SEQ ID NO: 1 and SEQ ID NO: 2 at least in that the at least one loop modification region comprises - a peptide insert sequence comprising at least 3 amino acids, so that the at least one loop modification region of the capsid protein sequence is extended with respect to the corresponding loop modification region of the amino acid sequences according to SEQ ID NO: 1 and SEQ ID NO: 2 by said number of amino acids; and/or - a cysteine residue, and Virus-like Nanoparticles (VLNPs) comprising such polypeptides.
6.WO/2025/232614USE OF ZEDOARONDIOL IN PREPARATION OF DRUG FOR PREVENTING, TREATING, AND INHIBITING LUNG CANCER
WO - 13.11.2025
Int.Class A61K 31/122
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
12Ketones
122having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
 Appl.No PCT/CN2025/091669 Applicant XIYUAN HOSPITAL, CHINA ACADEMY OF CHINESE MEDICAL SCIENCES Inventor SHI, Dazhuo
The present invention relates to the technical field of traditional Chinese medicine. Disclosed is use of zedoarondiol in the preparation of a drug for preventing, treating, and inhibiting lung cancer. It has been discovered that zedoarondiol can effectively induce apoptosis of A549 cells, inhibit the growth of non-small cell lung cancer, significantly inhibit the migration of A549 cells, hinder the development of non-small cell lung cancer, and simultaneously inhibit tumor growth. The present invention provides new use of zedoarondiol, expanding the medical application of zedoarondiol and offering a new technical means for lung cancer treatment.
7.20250340565CD73 INHIBITOR COMPOUNDS
US - 06.11.2025
Int.Class C07D 495/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
495Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
 Appl.No 18869980 Applicant AdoRx Therapeutics Limited Inventor Clive McCarthy

The present invention relates to compounds of formula I shown below:

embedded image

wherein R1, X2, X3, X4, X5 X6, X7, X8 and X9 are each as defined in the application. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or conditions in which adenosine CD73 activity is implicated, such as, for example, cancer.

8.20250339569CARBONIC ANHYDRASE IX LIGANDS
US - 06.11.2025
Int.Class A61K 51/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
51Preparations containing radioactive substances for use in therapy or testing in vivo
02characterised by the carrier
04Organic compounds
08Peptides, e.g. proteins
 Appl.No 18720400 Applicant 3B PHARMACEUTICALS GMBH Inventor Frank OSTERKAMP

The present invention relates to a chemical compound; a peptide; a Carbonic Anhydrase IX (CAIX) binding compound; a CAIX binding peptide; a composition comprising the compound; a composition comprising the CAIX binding compound; a composition comprising the peptide; a composition comprising the CAIX peptide; the compound, CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively, for use in a method for the diagnosis of a disease; the compound, the CAIX binding compound and the compositions, respectively, for use in a method for the treatment of a disease; the compound, the CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively, for use in a method of diagnosis and treatment of a disease; the compound, the CAIX binding compound, the peptide, the CAIX peptide, and the compositions, respectively, for use in a method for delivering a radionuclide to a CAIX expressing tissue; a method for the diagnosis of a disease using the compound, the CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively; a method for the treatment of a disease using the compound, the CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively; a method for the diagnosis and treatment of a disease using the compound, the CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively; a method for the delivery of a radionuclide to a CAIX expressing tissue using the compound, the CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively.

9.20250339367ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES
US - 06.11.2025
Int.Class A61K 9/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
 Appl.No 19197655 Applicant Aquestive Therapeutics, Inc. Inventor Alexander Mark Schobel

An oral film in an individual unit dose for delivery of one or more actives is disclosed herein, the film having a precisely calculated and controlled active dissolution profile. A wide variety of actives may be used, including, for example, clobazam, diazepam, or riluzole. Also disclosed are methods of treating a variety of diseases and conditions, for example, epilepsy and seizures, by administering the oral film disclosed herein.

10.20250340508TETRAHYDRO-1H-CYCLOPENTA[CD]INDENE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS
US - 06.11.2025
Int.Class C07C 255/54
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
255Carboxylic acid nitriles
49having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
54containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
 Appl.No 19270361 Applicant NIKANG THERAPEUTICS, INC. Inventor Jiping FU

The present disclosure provides certain tetrahydro-1H-cyclopenta[cd]indene compounds that are Hypoxia Inducible Factor 2α (HIF-2α) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of HIF-2α. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

# -